Search Results for /index.cfm/fuseaction/article.show/id/2/article_id/2249

Results for "/index.cfm/fuseaction/article.show/id/2/article_id/2249"

Tecentriq Combo Improves Response Rates in Early TNBC, Regardless of PD-L1 Status

September 22, 2020

Findings from a randomized phase 3 study showed that adding neoadjuvant Tecentriq to a chemotherapy regimen of Abraxane, Adriamycin and Cytoxan in patients with stage 2 or 3 triple-negative breast cancer significantly improved pathologic complete responses, compared with placebo plus chemotherapy.

Copiktra Plus Chemotherapy Needs Further Study of Toxicities in Patients With CLL

September 02, 2020

An early phase 1b/2 study of Copiktra in combination of standard of care shows how the treatment is active for patients with chronic lymphocytic leukemia but further study is needed to ensure it is an effective and safe alternative to standard of care.

Phase 2 Interim Analysis Shows Improved Response in Patients with Follicular Lymphoma

August 12, 2020

“These results further support our efforts to reimagine medicine in this incurable malignancy and reach this underserved patient population, who are historically burdened with several years of various treatments,” said Dr. John Tsai.

Patients with Cancer Experiencing COVID-19 Symptoms at Increased Risk of Death Despite Negative SARS-CoV-2 Tests

July 20, 2020

“These observations strongly suggest an underdiagnosis of COVID-19 in this population of cancer patients and a major underestimation of SARS-CoV-2 contribution as a cause of death in cancer patients,” the authors wrote. “The management of cancer patients with febrile respiratory symptoms in this period of the epidemic should, therefore, be particularly careful even in the absence of SARS-CoV-2 detection.”

Combination of Avastin and Tarceva 'Should Be Considered Preferred Option' in Kidney Cancer Subtype

July 10, 2020

Data from a phase 2 study presented during the 2020 ASCO Virtual Scientific Program demonstrated that Avastin (bevacizumab) in combination with Tarceva (erlotinib) was well tolerated and produced encouraging clinical outcomes in patients with advanced hereditary leiomyomatosis and renal cell carcinoma or sporadic papillary renal cell carcinoma.

Friday Frontline: Cancer Updates, Research and Education on July 2, 2020

July 03, 2020

From a care team giving a patient with metastatic breast cancer a taste of Paris after a planned trip had to be canceled to a local group of veterans honoring one of their own after a lung cancer diagnosis, here’s what’s making the headlines in the cancer space this week.

Friday Frontline: Cancer Updates, Research and Education on June 4, 2020

June 05, 2020

From the Food and Drug Administration asking pharmaceutical companies to voluntarily recall metformin, a type 2 diabetes medication, as it contains high levels of the cancer-causing contaminant NDMA to an NHL team’s fanbase showing support to a player as he finishes treatment for Ewing sarcoma, here’s what is making the headlines in the cancer space this week.

x